PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21508937-2	2011	In vitro, we found that imatinib is transported by the intestinal uptake carrier organic anion transporting polypeptide (OATP1A2) and that this process is sensitive to pH, rosuvastatin, and genetic variants.	Rosuvastatin Calcium	172-184	solute carrier organic anion transporter family member 1A2	Homo sapiens	121-128	
24628404-5	2014	The results showed that OATP-mediated uptake of rosuvastatin, a substrate for OATPs declined substantially in cultured human hepatocytes.	Rosuvastatin Calcium	48-60	solute carrier organic anion transporter family member 1A2	Homo sapiens	24-28	
21717139-6	2011	Therefore, the present results suggested that the potential drug interaction between danshensu or ursolic acid and rosuvastatin may be mediated by one or more transporters (OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP) and/or CYPs.	Rosuvastatin Calcium	115-127	solute carrier organic anion transporter family member 1A2	Homo sapiens	192-200	
23401473-6	2013	Furthermore, silymarin, silybin A, and silybin B (100 microM) significantly inhibited OATP-mediated estradiol-17beta-glucuronide and rosuvastatin uptake into human hepatocytes.	Rosuvastatin Calcium	133-145	solute carrier organic anion transporter family member 1A2	Homo sapiens	86-90	
21717139-5	2011	Rosuvastatin is a substrate of drug transporters such as human OATP1B1, OATP 1B3, OATP 1A2, BCRP and NTCP.	Rosuvastatin Calcium	0-12	solute carrier organic anion transporter family member 1A2	Homo sapiens	82-90	
28745105-10	2018	The inhibition of the hOATP1A2-mediated transport of rosuvastatin by these flavonoids was weaker.	Rosuvastatin Calcium	53-65	solute carrier organic anion transporter family member 1A2	Homo sapiens	22-30	
33037044-0	2020	Calibrating the in vitro-in vivo correlation for OATP mediated drug-drug interactions with rosuvastatin using static and PBPK models.	Rosuvastatin Calcium	91-103	solute carrier organic anion transporter family member 1A2	Homo sapiens	49-53	
16697742-7	2006	RESULTS: Multiple OATP family members, including 1B1, 1B3, 2B1, and 1A2, were capable of rosuvastatin transport.	Rosuvastatin Calcium	89-101	solute carrier organic anion transporter family member 1A2	Homo sapiens	18-22	
25908246-8	2015	OATP1A2-mediated uptake of zolmitriptan, rosuvastatin, and fexofenadine across monolayers increased with increasing OATP1A2 protein expression.	Rosuvastatin Calcium	41-53	solute carrier organic anion transporter family member 1A2	Homo sapiens	0-7	
29703388-4	2018	Putative mechanisms involve inhibitory effects of GT catechins at the intestinal level on influx transporters OATP1A2 or OATP2B1 for rosuvastatin, on CYP3A for sildenafil and on both CYP3A and the efflux transporter p-glycoprotein for tacrolimus.	Rosuvastatin Calcium	133-145	solute carrier organic anion transporter family member 1A2	Homo sapiens	110-117	
27737931-1	2017	Rosuvastatin is a widely prescribed antihyperlipidemic which undergoes limited metabolism, but is an in vitro substrate of multiple transporters [organic anion transporting polypeptide 1B1 (OATP1B1), OATP1B3, OATP1A2, OATP2B1, sodium-taurocholate cotransporting polypeptide, breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), MRP4, organic anion transporter 3].	Rosuvastatin Calcium	0-12	solute carrier organic anion transporter family member 1A2	Homo sapiens	209-216	
25858254-9	2016	They also inhibited OATP-mediated uptake of atorvastatin, fluvastatin, and rosuvastatin.	Rosuvastatin Calcium	75-87	solute carrier organic anion transporter family member 1A2	Homo sapiens	20-24	
25908246-10	2015	A three-compartment model incorporating OATP1A2-mediated influx was used to quantitatively describe the time- and concentration-dependent apical-to-basolateral transcellular transport of rosuvastatin across OATP1A2 expressing the MDCKII monolayer.	Rosuvastatin Calcium	187-199	solute carrier organic anion transporter family member 1A2	Homo sapiens	40-47	
25908246-10	2015	A three-compartment model incorporating OATP1A2-mediated influx was used to quantitatively describe the time- and concentration-dependent apical-to-basolateral transcellular transport of rosuvastatin across OATP1A2 expressing the MDCKII monolayer.	Rosuvastatin Calcium	187-199	solute carrier organic anion transporter family member 1A2	Homo sapiens	207-214	
25563901-3	2015	The primary objective of this study was to investigate OATP1A2 transport activity using rosuvastatin as a probe substrate and evaluate competitive inhibition of its transport by beta-blockers.	Rosuvastatin Calcium	88-100	solute carrier organic anion transporter family member 1A2	Homo sapiens	55-62	
25740267-2	2015	To understand the relevance of these in vitro findings, a clinical pharmacokinetic DDI study using rosuvastatin as a BCRP, OATP, and OAT3 probe substrate was conducted.	Rosuvastatin Calcium	99-111	solute carrier organic anion transporter family member 1A2	Homo sapiens	123-127	
25563901-5	2015	With the exception of carvedilol (IC50 of 3.2 microM), all of the other beta-blockers that were evaluated had a small or insignificant effect on OATP1A2-mediated uptake of rosuvastatin.	Rosuvastatin Calcium	172-184	solute carrier organic anion transporter family member 1A2	Homo sapiens	145-152	
25563901-9	2015	On the other hand, tricyclic compounds with a short aliphatic amine chain inhibited OATP1A2-mediated rosuvastatin transport.	Rosuvastatin Calcium	101-113	solute carrier organic anion transporter family member 1A2	Homo sapiens	84-91